Both anti-PD-1/PD-L1 therapy and EGFR-TKIs are considered as vital breakthroughs in the management of advanced NSCLC and are credited for changing this once dismal history of previously treated advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.